Skip to main content
Journal cover image

Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.

Publication ,  Journal Article
Alvarez Secord, A; Bae-Jump, V; Havrilesky, LJ; Calingaert, B; Clarke-Pearson, DL; Soper, JT; Gehrig, PA
Published in: Int J Gynecol Cancer
April 2009

OBJECTIVE: To assess the attitudes regarding the use of colony-stimulating factor (CSF) and the maintenance of relative dose intensity (RDI) by gynecologic oncologists during the administration of chemotherapy to patients with epithelial ovarian cancer. METHODS: A nationwide survey of 608 gynecologic oncologists was performed using a 19-point questionnaire. The questionnaire assessed the following domains: (1) demographic information, (2) patterns of CSF use during first-line and relapse chemotherapies for patients with epithelial ovarian cancer, and (3) use of CSFs to maintain RDI. RESULTS: The response rate to the survey was 42% (n = 255). Eighty-six percent (220/255) of the respondents routinely administer chemotherapy. In the first-line setting, 67% of physicians who routinely administer chemotherapy preferred to use CSFs for secondary prophylaxis after a neutropenic complication, whereas only 2% would use CSFs for primary prophylaxis. In the recurrent disease setting, physicians were more likely to administer a regimen with minimal myelosuppression (74% reported "likely" or "very likely"), to dose delay or modify if neutropenic complications occur (78%), or to administer CSFs for secondary prophylaxis (85%) than to dose attenuate upon initiation of chemotherapy (49%) or to administer CSFs for primary prophylaxis (46%). Most physicians would administer CSFs to maintain RDI in both the first-line (75%) and palliative settings (62%), and 49% would strive to maintain a dose intensity of more than 85%. CONCLUSIONS: Most gynecologic oncologists use CSFs as secondary prophylaxis for neutropenic complications rather than as primary prophylaxis. Most gynecologic oncologists monitor RDI and use CSFs to maintain RDI in their patients with ovarian carcinoma.

Duke Scholars

Published In

Int J Gynecol Cancer

DOI

EISSN

1525-1438

Publication Date

April 2009

Volume

19

Issue

3

Start / End Page

447 / 454

Location

England

Related Subject Headings

  • Practice Patterns, Physicians'
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Male
  • Humans
  • Genital Neoplasms, Female
  • Female
  • Drug Utilization
  • Dose-Response Relationship, Drug
  • Colony-Stimulating Factors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alvarez Secord, A., Bae-Jump, V., Havrilesky, L. J., Calingaert, B., Clarke-Pearson, D. L., Soper, J. T., & Gehrig, P. A. (2009). Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer, 19(3), 447–454. https://doi.org/10.1111/IGC.0b013e3181a1a6c9
Alvarez Secord, Angeles, Victoria Bae-Jump, Laura J. Havrilesky, Brian Calingaert, Daniel L. Clarke-Pearson, John T. Soper, and Paola A. Gehrig. “Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.Int J Gynecol Cancer 19, no. 3 (April 2009): 447–54. https://doi.org/10.1111/IGC.0b013e3181a1a6c9.
Alvarez Secord A, Bae-Jump V, Havrilesky LJ, Calingaert B, Clarke-Pearson DL, Soper JT, et al. Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer. 2009 Apr;19(3):447–54.
Alvarez Secord, Angeles, et al. “Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.Int J Gynecol Cancer, vol. 19, no. 3, Apr. 2009, pp. 447–54. Pubmed, doi:10.1111/IGC.0b013e3181a1a6c9.
Alvarez Secord A, Bae-Jump V, Havrilesky LJ, Calingaert B, Clarke-Pearson DL, Soper JT, Gehrig PA. Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer. 2009 Apr;19(3):447–454.
Journal cover image

Published In

Int J Gynecol Cancer

DOI

EISSN

1525-1438

Publication Date

April 2009

Volume

19

Issue

3

Start / End Page

447 / 454

Location

England

Related Subject Headings

  • Practice Patterns, Physicians'
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Male
  • Humans
  • Genital Neoplasms, Female
  • Female
  • Drug Utilization
  • Dose-Response Relationship, Drug
  • Colony-Stimulating Factors